Communiqués Sonnet BioTherapeutics Holdings, Inc.

Actions

SONN

US83548R4020

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 20/06/2025			Varia. 5j.	Varia. 1 janv.
1,190 ^USD	+2,15%		+3,48%	-18,49%

13/05	Sonnet BioTherapeutics Holdings, Inc. publie ses résultats pour le deuxième trimestre et le semestre clos le 31 mars 2025	CI
04/04	Sonnet BioTherapeutics déclare que son médicament contre le cancer de l'ovaire a montré des données d'innocuité "positives" dans l'essai de phase 1b/2a ; les actions sont en hausse	MT

Communiqués

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit	01/05	AQ
Sonnet Releases Virtual Investor "What This Means" Segment	16/04	AQ
Sonnet's SON-1010 demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose	07/04	AQ
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose	04/04	AQ
Sonnet Announces Release of Corporate Update Video	01/04	AQ
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.	01/04	AQ
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas	26/03	AQ
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein	19/03	AQ
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference	11/03	AQ
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors	26/02	AQ
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates	19/02	AQ
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference	18/02	AQ
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer	13/02	AQ
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update	13/02	AQ
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB Platform Technology	29/01	AQ
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology	28/01	AQ
Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar	22/01	AQ
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas	21/01	AQ
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment	23/12	AQ
Sonnet BioTherapeutics : Reports Fiscal Year 2024 Financial Results and Provides Corporate Update Form 8 K	17/12	PU
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update	17/12	AQ
Sonnet BioTherapeutics : Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules Form 8 K	10/12	PU
Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules	09/12	AQ
Sonnet BioTherapeutics : Announces Topline Safety Data Following Successful Completion of SON 1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial Form 8 K	09/12	PU
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial	09/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Sonnet BioTherapeutics Holdings, Inc.

Actions

SONN

US83548R4020

Recherche biotechnologique et médicale

Communiqués

Filtres